Accelerated Radiation Therapy for Lung Cancer

Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Recruiting Phase 1 Interventional Study
Lung Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
45 (estimated)
Sponsor
Stanford University · Other
Who this trial is looking for

This trial is looking for adults with locally advanced lung cancer who are receiving radiation therapy and other treatments. Participants will undergo a specific type of radiation therapy aimed at their tumor.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with lung cancer
  • I am at least 18 years old
  • I understand and can sign the consent form
  • I am expected to live 12 weeks or longer
  • I have an ECOG performance status of 0-2

You may not be able to join if

  • I am under 18 years old
  • I cannot receive radiation or other therapy as per my doctors
  • My tumor invades major blood vessels or vital organs
  • I have interstitial pulmonary fibrosis
  • I have had previous radiation therapy to my chest area that overlaps with the new treatment

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to examine the use of hypofractionated accelerated radiation therapy (HART) to treat locally advanced lung cancer. Depending on the location and size of the tumor.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * Age ≥ 18 ye…
Contacts

Aastha Dubey

650-725-2084

adubey7@stanford@stanford.edu

CONTACT

Sonya Boyd

650-723-2732

boydso@stanford.edu

CONTACT